Spineart Gains FDA Approval for BAGUERA C Cervical Disc
Geneva, Switzerland, August,11, 2026 Spineart has announced that its BAGUERA® C cervical disc has received U.S. Food and Drug...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Geneva, Switzerland, August,11, 2026 Spineart has announced that its BAGUERA® C cervical disc has received U.S. Food and Drug...
Northbrook, Illinois, August,11, 2026 Kalohexis, Inc., a clinical-stage biotechnology company developing therapies that target the melanocortin system, has appointed...
London, UK – November 3, 2025 Actimed Therapeutics Ltd, a UK-based clinical-stage specialty pharmaceutical company, has announced the grant...
